We have shown for the first time that Dln-101 is an effective neuroprotector. It protects dopamine neurons during cellular stress and its efficacy is higher than ghrelin’s. Dln-101’s neuroprotection, similar to ghrelin’s, is UCP2 dependent. Dln-101 was also shown to induce direct activation of dopamine neurons when applied directly to the brain or when injected peripherally (i.p.). The peptides Dln-101 and ghrelin in all studies conducted acted in a similar way with some advantage to Dln-101. Based on the pharmacokinetics and pharmacodynamics studies conducted, we conclude that Dln-101’s profile in plasma is similar to ghrelin’s. Dln-101’s half-life is longer than ghrelin’s, and, in addition, Dln-101 is more stable in plasma.